2008 turned out to be an exciting and important year for completing large drug discovery milestones at Nutra Pharma.  As the year quickly comes to a close, I wanted to take a moment to reflect back on our top accomplishments…

Medical Devices

• We began developing and marketing through our medical devices subsidiary, Designer Diagnostics, the first-ever environmental test kit for the rapid detection of Nontuberculous Mycobacteria

Drug Discovery

• We acquired the remaining interest in our drug discovery holding, ReceptoPharm, which transitioned it into a Nutra Pharma wholly-owned subsidiary
• We received final approval from the Florida Department of Agriculture and Consumer Services to begin a trial using RPI-MN for treating Feline Leukemia Virus (FeLV). This study will not only help us develop a possible model for studying RPI-MN as a treatment for HIV in humans, but if successful, RPI-MN will be the first-ever treatment for FeLV, a virus that currently affects 2% to 3% of the cat population in the United States
• We successfully completed a 15-month Phase IIb/IIIa trial using RPI-78M as a treatment for Adrenomyeloneuropathy (AMN). We expect the fully-audited results from this study to be available in early 2009
• In addition to completing this Phase IIb/IIIa clinical trial, we also announced that initial reports and feedback from physicians involved with this study reported that patients had experienced no adverse side effects from RPI-78M. This led us to the decision to continue providing RPI-78M under compassionate release to patients previously enrolled in the study
• We renewed our collaborative agreement with the Centers for Disease Control and Prevention (CDC) to study RPI-78M and RPI-MN as a possible therapy for Rabies
• We received our first clinical drug supply contract from Celtic Biotech in Dublin, Ireland, which represented the first revenue for our drug discovery subsidiary, ReceptoPharm. As we continue into 2009, we plan to expand this outsourced drug production to additional biotechnology firms. This will allow us to fully utilize our GMP-qualified production facility and will also provide us with an additional revenue stream

Additional Outreach

• We re-launched our corporate blog to help build transparency between Nutra Pharma and those interested in our drug discovery research and corporate strategy
• We were mentioned in several articles published in various pharmaceutical industry trade publications
• We received an invitation by BlogBurst to extend the reach of our blog postings to be included in media outlets such as USA Today, Gannett, Reuters, FoxNews, Houston Chronicle and many others

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Nutra Pharma’s 2008 Accomplishments", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

               

Comments

No comments yet.

RSS feed for comments on this post.

TrackBack URL

Leave a Comment

Name (required)

Email (will not be published) (required)

Website